Gene Delivery Using Viral Vectors - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 262

[92] Kaplitt MG, Feigin A, Tang C. Safety and tolerability of gene therapy with an adeno-
associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I
trial. Lancet 2007;369:2097-105.
[93] Erles K, Rohde V, Thaele M, Roth S, Edler L, Schlehofer JR. DNA of adeno-associ-
ated virus (AAV) in testicular tissue and in abnormal semen samples. Hum Reprod
2001;16:2333-7.
[94] Bohenzky RA, LeFebvre RB, Berns KI. Sequence and symmetry requirements within
the internal palindromic sequences of the adeno-associated virus terminal repeat.
Virology 1988;166:316-27.
[95] Wang XS, Ponnazhagan S, Srivastava A. Rescue and replication signals of the adeno-
associated virus 2 genome. J Mol Biol 1995;250:573-80.
[96] Weitzman MD, Kyöstiö SR, Kotin RM, Owens RA. Adeno-associated virus (AAV)
rep proteins mediate complex formation between AAV DNA and its integration site in
human DNA. Proc Natl Acad Sci U.S.A. 1994;91:5808-12.
[97] Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. J Virol
1998;72:3241-7.
[98] Muzyczka N. Use of adeno-associated virus as a generalized transduction vector in
mammalian cells. Curr Topics Microbiol Immunol 1992;158:97-129.
[99] Carter BJ. Adeno-associated virus vectors. Curr Opin Biotechnol 1992;3:533-39.
[100] Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther
1995:2357-62.
[101] Flotte TR, Zeitlin PL, Solow Afione S, Owens RA, Markakis D, Drumm M, et al.
Expression of the cystic fibrosis transmembrane conductanceregulator from a novel
adeno-associated virus promoter. J Biol Chem 1993;268:3781-90.
[102] Haberman RP, McCown TJ, Samulski RJ. Novel transcriptional regulatory signals
in the adeno-associated virus terminal repeat A/D junction element. J Virol 2000;74:
8732-9.
[103] Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Reier PJ. Efficient transduction
of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors
containing cell type-specific promoters. Gene Ther 1997;4:16-24.
[104] Flannery JG, Zolotukhin S, Vaquero MI, LaVail MM, Muzyczka N, Hauswirth WW.
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associ-
ated virus. Proc Natl Acad Sci U.S.A. 1997;94:6916-21.
[105] Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of
immunocompetent mice by adeno-associated virus vector. J Virol 1996;70:8098-108.
[106] Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, et al. Sustained secretion of
human alpha-l-antitrypsin from murine muscle transduced with adeno-associated virus
vectors. Proc Natl Acad Sci U.S.A. 1998;95:14384-8.
[107] Yang Q, Chen F, Trempe JP. Characterization of cell lines that inducibly express the
adeno-associated virus rep proteins. J Virol 1994;68:4847-56.
[108] Allen JA, Debelak DJ, Reynolds TC, Miller AD. Identification and elimination of rep-
lication-competent adeno-associated virus (AAV) that can arise by non-homologous
recombination during AAV vector production. J Virol 1997;71:6816-22.
[109] Wang XS, Khuntirat B, Qing K, Ponnazhagan S, Kube DM, Zhou S, et al. A charac-
terization of wild-type adeno-associated virus type 2-like particles generated dur-
ing recombinant viral vector production and strategies for their elimination. J Virol
1998;72:5472-80.
[110] Fan PD, Dong JY. Replication of rep-cap genes is essential or the high-efficiency pro-
duction of recombinant AAV. Hum Gene Ther 1997;8:87-98.